Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Respiratory Mucosa in Patients with Chronic Obstructive Pulmonary Dysfunction
*Corresponding Author:Received Date: Dec 30, 2023 / Published Date: Nov 29, 2023
Citation: Kjell EJH (2023) Respiratory Mucosa in Patients with Chronic Obstructive Pulmonary Dysfunction. J Respir Med 5: 185.DOI: 10.4172/jrm.1000185
Copyright: © 2023 Kjell EJH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The vast majority of pulmonary medications are used to promote broncho-dilation and improve alveolar ventilation and oxygenation. These effects should improve an individual's ability to exercise and more effectively develop training effects. Because of the side effects of many pulmonary medications, however, exercise tolerance and the normal adaptations to habitual exercise conditioning may be retarded. The following section is not presented to discourage the use of these medications nor of exercise training; rather, it should highlight the important role exercise has for patients with pulmonary disease who are taking pulmonary medications.
